Sodium-Dependent Glucose Transporter Type 2 Inhibitors as a Breakthrough in Neutropenia and Neutrophil Dysfunction Management in Patients with Glycogen Storage Disease Type Ib
Glycogen storage disease type Ib (GSD Ib) is a rare and extremely severe disease included in the group of hereditary carbohydrate metabolism disorders. The condition is caused by pathogenic variants in the SLC37A4 gene leading to glucose metabolic disorder in the liver and kidneys, and as a result t...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2024-07-01
|
| Series: | Вопросы современной педиатрии |
| Subjects: | |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/3521 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839575300687527936 |
|---|---|
| author | Andrey N. Surkov Leyla S. Namazova-Baranova Anna L. Arakelyan Evgeny E. Bessonov Natalia V. Zhurkova |
| author_facet | Andrey N. Surkov Leyla S. Namazova-Baranova Anna L. Arakelyan Evgeny E. Bessonov Natalia V. Zhurkova |
| author_sort | Andrey N. Surkov |
| collection | DOAJ |
| description | Glycogen storage disease type Ib (GSD Ib) is a rare and extremely severe disease included in the group of hereditary carbohydrate metabolism disorders. The condition is caused by pathogenic variants in the SLC37A4 gene leading to glucose metabolic disorder in the liver and kidneys, and as a result to severe organomegaly, hypoglycemia, and metabolic decompensation. Moreover, neutropenia and neutrophil dysfunction are noted in patients with GSD Ib. The use of granulocyte colony stimulating factor only increases the number of dysfunctional neutrophils without affecting their functional activity, what determines the inefficacy of such treatment. In recent years, the mechanism of neutropenia in GSD Ib has been clarified, so new therapeutic agents for its relief have been created. This article presents the overview of data on the successful results of renal sodium-glucose cotransporter type 2 inhibitors (gliflozins) usage in patients with GSD Ib. |
| format | Article |
| id | doaj-art-8b4ab6f90c7b4f8b855be3182c18ab2f |
| institution | Matheson Library |
| issn | 1682-5527 1682-5535 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | "Paediatrician" Publishers LLC |
| record_format | Article |
| series | Вопросы современной педиатрии |
| spelling | doaj-art-8b4ab6f90c7b4f8b855be3182c18ab2f2025-08-04T13:09:42Zeng"Paediatrician" Publishers LLCВопросы современной педиатрии1682-55271682-55352024-07-0123316216710.15690/vsp.v23i3.27612175Sodium-Dependent Glucose Transporter Type 2 Inhibitors as a Breakthrough in Neutropenia and Neutrophil Dysfunction Management in Patients with Glycogen Storage Disease Type IbAndrey N. Surkov0Leyla S. Namazova-Baranova1Anna L. Arakelyan2Evgeny E. Bessonov3Natalia V. Zhurkova4Research Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery; Pirogov Russian National Research Medical UniversityResearch Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery; Pirogov Russian National Research Medical UniversityResearch Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of SurgeryResearch Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of SurgeryResearch Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of SurgeryGlycogen storage disease type Ib (GSD Ib) is a rare and extremely severe disease included in the group of hereditary carbohydrate metabolism disorders. The condition is caused by pathogenic variants in the SLC37A4 gene leading to glucose metabolic disorder in the liver and kidneys, and as a result to severe organomegaly, hypoglycemia, and metabolic decompensation. Moreover, neutropenia and neutrophil dysfunction are noted in patients with GSD Ib. The use of granulocyte colony stimulating factor only increases the number of dysfunctional neutrophils without affecting their functional activity, what determines the inefficacy of such treatment. In recent years, the mechanism of neutropenia in GSD Ib has been clarified, so new therapeutic agents for its relief have been created. This article presents the overview of data on the successful results of renal sodium-glucose cotransporter type 2 inhibitors (gliflozins) usage in patients with GSD Ib.https://vsp.spr-journal.ru/jour/article/view/3521glycogen storage disease type ibneutropeniagranulocyte colony-stimulating factorsodium-glucose cotransporter type 2 inhibitorsgliflozins |
| spellingShingle | Andrey N. Surkov Leyla S. Namazova-Baranova Anna L. Arakelyan Evgeny E. Bessonov Natalia V. Zhurkova Sodium-Dependent Glucose Transporter Type 2 Inhibitors as a Breakthrough in Neutropenia and Neutrophil Dysfunction Management in Patients with Glycogen Storage Disease Type Ib Вопросы современной педиатрии glycogen storage disease type ib neutropenia granulocyte colony-stimulating factor sodium-glucose cotransporter type 2 inhibitors gliflozins |
| title | Sodium-Dependent Glucose Transporter Type 2 Inhibitors as a Breakthrough in Neutropenia and Neutrophil Dysfunction Management in Patients with Glycogen Storage Disease Type Ib |
| title_full | Sodium-Dependent Glucose Transporter Type 2 Inhibitors as a Breakthrough in Neutropenia and Neutrophil Dysfunction Management in Patients with Glycogen Storage Disease Type Ib |
| title_fullStr | Sodium-Dependent Glucose Transporter Type 2 Inhibitors as a Breakthrough in Neutropenia and Neutrophil Dysfunction Management in Patients with Glycogen Storage Disease Type Ib |
| title_full_unstemmed | Sodium-Dependent Glucose Transporter Type 2 Inhibitors as a Breakthrough in Neutropenia and Neutrophil Dysfunction Management in Patients with Glycogen Storage Disease Type Ib |
| title_short | Sodium-Dependent Glucose Transporter Type 2 Inhibitors as a Breakthrough in Neutropenia and Neutrophil Dysfunction Management in Patients with Glycogen Storage Disease Type Ib |
| title_sort | sodium dependent glucose transporter type 2 inhibitors as a breakthrough in neutropenia and neutrophil dysfunction management in patients with glycogen storage disease type ib |
| topic | glycogen storage disease type ib neutropenia granulocyte colony-stimulating factor sodium-glucose cotransporter type 2 inhibitors gliflozins |
| url | https://vsp.spr-journal.ru/jour/article/view/3521 |
| work_keys_str_mv | AT andreynsurkov sodiumdependentglucosetransportertype2inhibitorsasabreakthroughinneutropeniaandneutrophildysfunctionmanagementinpatientswithglycogenstoragediseasetypeib AT leylasnamazovabaranova sodiumdependentglucosetransportertype2inhibitorsasabreakthroughinneutropeniaandneutrophildysfunctionmanagementinpatientswithglycogenstoragediseasetypeib AT annalarakelyan sodiumdependentglucosetransportertype2inhibitorsasabreakthroughinneutropeniaandneutrophildysfunctionmanagementinpatientswithglycogenstoragediseasetypeib AT evgenyebessonov sodiumdependentglucosetransportertype2inhibitorsasabreakthroughinneutropeniaandneutrophildysfunctionmanagementinpatientswithglycogenstoragediseasetypeib AT nataliavzhurkova sodiumdependentglucosetransportertype2inhibitorsasabreakthroughinneutropeniaandneutrophildysfunctionmanagementinpatientswithglycogenstoragediseasetypeib |